Trial supports immunoglobulin in post-polio patients
Positive results from a Phase II/III clinical trial evaluating Grifols’ intravenous immunoglobulin (IVIG) to treat patients with post-polio syndrome (PPS) have demonstrated a significant improvement in distance walked compared to placebo.
The immunomodulatory properties of IVIG – in this case Flebogamma 5% DIF (immune globulin intravenous [human]) – are believed to have a role in potentially improving this disabling condition.
“This study is great news since it proves that the ongoing decline in physical functioning due to post-polio syndrome, which was so far considered inevitable, can be halted, and even be improved,” said Dr Frans Nollet, of the Department of Rehabilitation Medicine of the Academic Medical Center, University of Amsterdam, and one of the study’s principal investigators. “That is positive for all polio survivors, who are confronted with increasing disabilities as they age and for whom no effective medication was yet available.”
The study met its primary endpoint of enhanced physical performance in the two-minute walk distance (2MWD) after the one-year treatment period.
Patients who received monthly IVIG infusions of 1g/kg showed a statistically significant improvement in 2MWD versus placebo.
The least squares mean 2MWD change from baseline at week 52, after adjusting for differences between groups, was 12.75 meters, equating to a mean improvement of 6.07 meters over placebo.
A meaningful physical improvement
Treated patients with IVIG 1g/Kg also showed greater numerical endurance as measured by the six-minute walk distance (6MWD). The least squares mean 6MWD change from baseline at week 52, after adjusting for differences between groups, was 29.16 meters, which equates to a mean improvement of 15.8 meters over placebo.
PPS can emerge decades after an initial polio infection. Symptoms – including chronic fatigue, joint and muscle pain, persistent and progressive muscle weakness and atrophy – typically develop 30 to 40 years after the initial paralytic attack and tend to worsen over time.
There are no medications indicated for the syndrome, and therapies are limited to supportive measures such as orthoses and other assistive devices, as well as symptom management.
“These results show a meaningful physical accomplishment, providing patients with more freedom of movement and the ability to be more self-reliant,” said Dr Jörg Schüttrumpf, Grifols Chief Scientific Innovation Officer. “Grifols is committed to increasing the range of indications of its plasma-derived medicines and other biopharmaceuticals to benefit more patients globally and make a real positive difference in their lives.”
Diana Spencer, Senior Digital Content Editor, DDW
